Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corporation develops medical technology for surgical diagnosis and treatment of neurological disorders. The company’s platform centers on thin-film electrode technology used in recording, monitoring, mapping, ablation and brain stimulation applications, including Evo Cortical, Evo sEEG and the OneRF Ablation System.
NeuroOne news commonly covers FDA 510(k) clearances, product applications for epilepsy, facial pain and other neurosurgical uses, patent activity around neural probe and electrode technologies, financial results, capital raises, commercial orders, investor conferences and management updates. Coverage also reflects the company’s efforts to extend the OneRF platform into additional ablation, stimulation and drug-delivery applications.
NeuroOne Medical Technologies (NASDAQ: NMTC) reported its financial results for Q2 FY2024, ending March 31, 2024. Product revenue increased to $1,377,000 from $466,000 in Q2 FY2023. The company raised an additional $2 million through the ATM Program. Key product updates include the commercial launch of the OneRF Ablation System and expanded use of the Evo sEEG system by Zimmer Biomet.
R&D expenses decreased to $1.3 million, while SG&A expenses rose to $2 million. Total operating expenses were $3.3 million. The net loss dropped to $2.9 million from $3.5 million in Q2 FY2023. Cash and cash equivalents fell to $2.4 million from $5.3 million as of September 2023.
Key upcoming milestones include transitioning to OneRF electrodes, enhancing the drug delivery program, and refining the spinal cord stimulation program.
NeuroOne Medical Technologies (NMTC) will host a conference call and webcast on May 14, 2024, to discuss the financial results for its second quarter of fiscal year 2024 and provide a corporate update. The company focuses on improving surgical care options and outcomes for patients with neurological disorders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.